References
- Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
- Ofran Y, Tallman MS, Rowe JM. How I treat acute myeloid leukemia presenting with preexisting comorbidities. Blood. 2016;128(4):488–496.
- DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
- DeWolf S, Tallman MS. How I treat relapsed or refractory AML. Blood. 2020;136(9):1023–1032.
- Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137–2145.
- Aldoss I, Yang D, Aribi A, et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica. 2018;103(9):e404–e407.
- DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93(3):401–407.
- Janus N, Launay-vacher V, Thyss A, et al. Management of anticancer treatment in patients under chronic dialysis: Results of the multicentric CANDY (CANcer and DialYsis) study. Ann Oncol. 2013;24(2):501–507.
- Kaminskas E, Farrell AT, Wang Y-C, et al. FDA drug approval summary: Azacitidine (5-azacytidine, VidazaTM) for injectable suspension. Oncologist. 2005;10(3):176–182.
- Ham JC, Hoogendijk-Van Den Akker JM, Verdonck LF. A hemodialysis patient with higher-risk myelodysplastic syndrome treated with standard-dose azacitidine. Leuk Lymphoma. 2012;53(12):2521–2522.
- Yoshihiro T, Muta T, Aoki K, et al. Efficacy and adverse events of azacitidine in the treatment of hemodialysis patients with high-risk myelodysplastic syndrome. Rinsho Ketsueki. 2016;57(8):1004–1010.
- Douvali E, Papoutselis M, Vassilakopoulos TP, et al. Safety and efficacy of 5-azacytidine treatment in myelodysplastic syndrome patients with moderate and mild renal impairment. Leuk Res. 2013;37(8):889–893.
- Batty GN, Kantarjian H, Issa J, et al. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. Clin Lymphoma Myeloma Leuk. 2010;10(3):205–210.
- Salem AH, Agarwal SK, Dunbar M, et al. Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or Non-Hodgkin lymphoma. J Clin Pharmacol. 2017;57(4):484–492.
- Swan D, Delaney C, Natoni A, et al. Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14). Haematologica. 2020;105(3):e141–e143.